DexCom, Inc. (NASDAQ:DXCM) Holdings Raised by Natixis Advisors LLC

Natixis Advisors LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 446.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 193,532 shares of the medical device company’s stock after acquiring an additional 158,124 shares during the period. Natixis Advisors LLC’s holdings in DexCom were worth $15,051,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DXCM. Jennison Associates LLC raised its stake in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. raised its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD acquired a new stake in DexCom in the fourth quarter valued at approximately $96,507,000. Westfield Capital Management Co. LP grew its position in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after purchasing an additional 739,000 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares of the company’s stock, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,657 shares of company stock valued at $8,019,422 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $70.70 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a fifty day moving average price of $83.64 and a 200 day moving average price of $76.95. The stock has a market cap of $27.63 billion, a P/E ratio of 49.44, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on DXCM shares. Canaccord Genuity Group lifted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.